UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

Ariad Pharma on the Top

Seite 2 von 373
neuester Beitrag: 26.09.16 18:45
eröffnet am: 17.01.14 10:56 von: Masterbroker. Anzahl Beiträge: 9314
neuester Beitrag: 26.09.16 18:45 von: Masterbroker. Leser gesamt: 1034179
davon Heute: 38
bewertet mit 36 Sternen

Seite: Zurück 1 |
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | 373  Weiter  

93 Postings, 2449 Tage MOT25@Zvier

 
  
    
17.01.14 12:20
Was ist denn am Montag?  

3007 Postings, 2176 Tage MasterbrokerUSAFeiertag

 
  
    
17.01.14 12:23

2472 Postings, 2578 Tage Zvier20.01.2014 Martin Luther King Day 2014 USA

 
  
    
1
17.01.14 12:24

93 Postings, 2449 Tage MOT25Vielen Dank

 
  
    
17.01.14 12:31

3795 Postings, 3801 Tage schultebrand#25, ich auch nicht....wer behauptet das denn.....

 
  
    
17.01.14 12:35

3007 Postings, 2176 Tage MasterbrokerUSASo

 
  
    
17.01.14 12:41
heute noch ein Green DAY zum Abscluss für die Woche.Dann haben wir alle 3 Tage frei und können dann hoffendlich staunen das Ariad übers WE Hammer News raus haut damit wir Montag bei 8 doller uf machen können ;-)  

1529 Postings, 3946 Tage deAlexna

 
  
    
17.01.14 12:46
jetzt gehts aber mit dir durch :-)

Und warum haben wir alle 3 Tage frei, ich muss Montag arbeiten ;-)

wenn wir schon dabei sind, wenn Eröffnen wir Dienstag mit USD denn Montag ist ja zu.
man man man.... ;-)
 

592 Postings, 2173 Tage CapretAriad war

 
  
    
3
17.01.14 12:50
vor 3 Tagen im Rampenlicht gestanden, all eyes on Aria. Wenn es "Hammer News" zu berichten gäbe, hätten sie das auf der JPM Konferenz getan oder? Also ich würde es jedenfalls so machen :)  

2981 Postings, 2493 Tage PackardbellNaja

 
  
    
17.01.14 12:55
News sind ja gekommen für mich auch sehr gute denke viele schauen auf die nächsten Zahlen bereits und darum ein gewisser Druck momentan ist.  

1529 Postings, 3946 Tage deAlex@Carpet

 
  
    
17.01.14 12:57
wäre ich mir nicht so sicher, das was sie präsentiert haben war durchweg positiv.

Ich als Investor würde dem sagen:
Junge sieht gut aus, ich steig ein aber lass mir dafür mal paar Tage Zeit.

So würde ich es machen.  

3007 Postings, 2176 Tage MasterbrokerUSAJa

 
  
    
17.01.14 13:03
alles kann Fakt ist Ariad geht es mit den aussichten gut kann,man anders nicht sagen eigendlich passt alles soweit und wer weiss was über das WE so weitere´s  so an News kommt  

592 Postings, 2173 Tage CapretKein

 
  
    
2
17.01.14 13:15
Missverständniss, ich bin Ariad Investor aus Überzeugung. Ich hatte die FDA Zulassung abgewartet, und bin nun stolzer Besitzer mehrerer Tausend Scheinchen dieser Firma.
Hab keine Bedenken, die Aktie wird sich entwickeln.

Die nächsten Hammernews erwarte ich allerdings erst am / gegen 24.02. um die durch den Verkaufsstop schlechten Quartalszahlen aufzuhübschen, wenn nicht sogar zu pulverisieren :)  

1529 Postings, 3946 Tage deAlexWiderstände?

 
  
    
17.01.14 13:17
1. nach oben kurz unter den 7 USD richtig?
Wenn der durch ist dann nächstes Ziel 7,75.

Alles klar jeder weiß bescheid, Attacke!  

21766 Postings, 4093 Tage Heron@Masterbroker

 
  
    
17.01.14 13:38
Mit Posting #19 haste dich doch verraten.

Wer biste denn eigentlich.

Weil soweit scheint dein Börsenwissen auch nicht zu sein.

Biste ein kleiner Kopierer-aus allen Foren ein bischen was?

Wünsch dir viel Glück  

1529 Postings, 3946 Tage deAlexes geht los

 
  
    
17.01.14 13:40
zurücklehnen de Show schau ich mir an  

1529 Postings, 3946 Tage deAlex$7.15* 0.41 + 6.08%

 
  
    
17.01.14 13:44

592 Postings, 2173 Tage CapretPre market

 
  
    
2
17.01.14 13:48
seht ihr das auch? >.<
da steppt der Bär...

High bei 7,35$

sind da ein paar short Optionen ausgelaufen? xD  

1529 Postings, 3946 Tage deAlexich sehe es :-)

 
  
    
17.01.14 13:49
scheint ja doch spannend zu werden.

Haben diese 100 Share Blöcke  eine Bedeutung?  

592 Postings, 2173 Tage CapretAh es gibt

 
  
    
2
17.01.14 13:50
neue News, siehe Ariad page  

592 Postings, 2173 Tage CapretNews releases

 
  
    
3
17.01.14 13:52

<< Back
ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 17, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the commercial availability of Iclusig® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

?We are pleased to again have Iclusig commercially available to patients in the United States,? stated Marty J. Duvall, executive vice president and chief commercial officer for ARIAD. ?Iclusig is now in our distribution channel with Biologics, and our dedicated sales force will begin promoting Iclusig immediately. We are highly confident in our commercial launch of Iclusig and look forward to reporting on our progress on a quarterly basis.?

Last month, the U.S. Food and Drug Administration (FDA) approved revised U.S. Prescribing Information (USPI) and a communications Risk Evaluation and Mitigation Strategy (REMS) for Iclusig that allowed for the immediate resumption of its marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information and recommendations regarding dosing considerations for prescribers. Iclusig is now indicated for the treatment of adult patients with:

   T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, or
   Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia for whom no other tyrosine-kinase inhibitor therapy is indicated.

The starting dose of Iclusig remains 45 mg daily.

On November 1, 2013, there were approximately 640 patients receiving Iclusig obtained through commercial channels in the U.S. Since then, Iclusig was made available through emergency and single-patient investigational new drug (IND) applications, which were reviewed and approved by the FDA on a case-by-case basis. The FDA has approved more than 370 INDs since early November, and more than 300 patients have received Iclusig at no cost through this process. ARIAD expects most of these patients, many of whom received a three-month supply of Iclusig, to transition from the IND program to commercial therapy by the end of the first quarter of 2014. The Iclusig IND program is now closed to new patients with Philadelphia-positive leukemias.

In addition to providing specialty pharmacy services, Biologics will help transition patients from the Iclusig IND program to commercial product. Biologics will further support the ARIAD Patient Access and Support Services (ARIAD PASS?) program by managing ARIAD?s reimbursement and patient access services and co-pay support programs by conducting benefits investigations and prior authorizations to assess and assist with patient eligibility. Iclusig is currently priced in the U.S. at approximately $125,000 per year. The new annual cost of Iclusig is approximately a 17 percent premium to second-generation TKIs.

For more information on Iclusig, please visit www.iclusig.com. For more information on the ARIAD PASS program, patients and physicians should call the U.S. toll-free phone number 1-855-447-PASS (7277).

About Iclusig® (ponatinib)

Iclusig is a kinase inhibitor. The primary target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIAD?s computational and structure-based drug-design platform specifically to inhibit the activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, a common mutation which has been associated with resistance to other approved TKIs.

IMPORTANT SAFETY INFORMATION, INCLUDING THE BOXED WARNING

WARNING: VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY

See full U.S. prescribing information for complete boxed warning

   Vascular Occlusion: Arterial and venous thrombosis and occlusions have occurred in at least 27% of Iclusig treated patients, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. Monitor for evidence of thromboembolism and vascular occlusion. Interrupt or stop Iclusig immediately for vascular occlusion. A benefit risk consideration should guide a decision to restart Iclusig therapy.
   Heart Failure, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening heart failure.
   Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected.

Vascular Occlusion: Arterial and venous thrombosis and occlusions, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures have occurred in at least 27% of Iclusig-treated patients from the phase 1 and phase 2 trials. Iclusig can also cause recurrent or multi-site vascular occlusion. Overall, 20% of Iclusig-treated patients experienced an arterial occlusion and thrombosis event of any grade. Fatal and life-threatening vascular occlusion has occurred within 2 weeks of starting Iclusig treatment and in patients treated with average daily dose intensities as low as 15 mg per day. The median time to onset of the first vascular occlusion event was 5 months. Patients with and without cardiovascular risk factors have experienced vascular occlusion although these events were more frequent with increasing age and in patients with prior history of ischemia, hypertension, diabetes, or hyperlipidemia. Interrupt or stop Iclusig immediately in patients who develop vascular occlusion events.

Heart Failure: Fatal and serious heart failure or left ventricular dysfunction occurred in 5% of Iclusig-treated patients (22/449). Eight percent of patients (35/449) experienced any grade of heart failure or left ventricular dysfunction. Monitor patients for signs or symptoms consistent with heart failure and treat as clinically indicated, including interruption of Iclusig. Consider discontinuation of Iclusig in patients who develop serious heart failure.

Hepatotoxicity: Iclusig can cause hepatotoxicity, including liver failure and death. Fulminant hepatic failure leading to death occurred in an Iclusig-treated patient within one week of starting Iclusig. Two additional fatal cases of acute liver failure also occurred. The fatal cases occurred in patients with blast phase CML (BP-CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Severe hepatotoxicity occurred in all disease cohorts. Iclusig treatment may result in elevation in ALT, AST, or both. Monitor liver function tests at baseline, then at least monthly or as clinically indicated. Interrupt, reduce or discontinue Iclusig as clinically indicated.

Hypertension: Treatment-emergent hypertension (defined as systolic BP≥140 mm Hg or diastolic BP≥90 mm Hg on at least one occasion) occurred in 67% of patients (300/449). Eight patients treated with Iclusig (2%) experienced treatment-emergent symptomatic hypertension as a serious adverse reaction, including one patient (<1%) with hypertensive crisis. Patients may require urgent clinical intervention for hypertension associated with confusion, headache, chest pain, or shortness of breath In 131 patients with Stage 1 hypertension at baseline, 61% (80/131) developed Stage 2 hypertension. Monitor and manage blood pressure elevations during Iclusig use and treat hypertension to normalize blood pressure. Interrupt, dose reduce, or stop Iclusig if hypertension is not medically controlled.

Pancreatitis: Clinical pancreatitis occurred in 6% (28/449) of patients (5% Grade 3) treated with Iclusig. Pancreatitis resulted in discontinuation or treatment interruption in 6% of patients (25/449). The incidence of treatment-emergent lipase elevation was 41%. Check serum lipase every 2 weeks for the first 2 months and then monthly thereafter or as clinically indicated. Consider additional serum lipase monitoring in patients with a history of pancreatitis or alcohol abuse. Dose interruption or reduction may be required. In cases where lipase elevations are accompanied by abdominal symptoms, interrupt treatment with Iclusig and evaluate patients for pancreatitis. Do not consider restarting Iclusig until patients have complete resolution of symptoms and lipase levels are less than 1.5 x ULN.

Neuropathy: Peripheral and cranial neuropathy have occurred in Iclusig-treated patients. Overall, 13% (59/449) of Iclusig-treated patients experienced a peripheral neuropathy event of any grade (2%, grade 3/4). In clinical trials, the most common peripheral neuropathies reported were peripheral neuropathy (4%, 18/449), paresthesia (4%, 17/449), hypoesthesia (2%, 11/449), and hyperesthesia (1%, 5/449). Cranial neuropathy developed in 1% (6/449) of Iclusig-treated patients (<1% grade 3/4).

Of the patients who developed neuropathy, 31% (20/65) developed neuropathy during the first month of treatment. Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain or weakness. Consider interrupting Iclusig and evaluate if neuropathy is suspected.

Ocular Toxicity: Serious ocular toxicities leading to blindness or blurred vision have occurred in Iclusig-treated patients. Retinal toxicities including macular edema, retinal vein occlusion, and retinal hemorrhage occurred in 3% of Iclusig-treated patients. Conjunctival or corneal irritation, dry eye, or eye pain occurred in 13% of patients. Visual blurring occurred in 6% of the patients. Other ocular toxicities include cataracts, glaucoma, iritis, iridocyclitis, and ulcerative keratitis. Conduct comprehensive eye exams at baseline and periodically during treatment.

Hemorrhage: Serious bleeding events, including fatalities, occurred in 5% (22/449) of patients treated with Iclusig. Hemorrhagic events occurred in 24% of patients. The incidence of serious bleeding events was higher in patients with accelerated phase CML (AP-CML), BP-CML, and Ph+ ALL. Most hemorrhagic events, but not all occurred in patients with grade 4 thrombocytopenia. Interrupt Iclusig for serious or severe hemorrhage and evaluate.

Fluid Retention: Serious fluid retention events occurred in 3% (13/449) of patients treated with Iclusig. One instance of brain edema was fatal. In total, fluid retention occurred in 23% of the patients. The most common fluid retention events were peripheral edema (16%), pleural effusion (7%), and pericardial effusion (3%). Monitor patients for fluid retention and manage patients as clinically indicated. Interrupt, reduce, or discontinue Iclusig as clinically indicated.

Cardiac Arrhythmias: Symptomatic bradyarrhythmias that led to a requirement for pacemaker implantation occurred in 1% (3/449) of Iclusig-treated patients. Advise patients to report signs and symptoms suggestive of slow heart rate (fainting, dizziness, or chest pain). Supraventricular tachyarrhythmias occurred in 5% (25/449) of Iclusig-treated patients. Atrial fibrillation was the most common supraventricular tachyarrhythmia and occurred in 20 patients. For 13 patients, the event led to hospitalization. Advise patients to report signs and symptoms of rapid heart rate (palpitations, dizziness). Interrupt Iclusig and evaluate.

Myelosuppression: Severe (grade 3 or 4) myelosuppression occurred in 48% (215/449) of patients treated with Iclusig. The incidence of these events was greater in patients with AP-CML, BP-CML and Ph+ ALL than in patients with CP-CML. Obtain complete blood counts every 2 weeks for the first 3 months and then monthly or as clinically indicated, and adjust the dose as recommended.

Tumor Lysis Syndrome: Two patients (<1%) with advanced disease (AP-CML, BP-CML, or Ph+ ALL) treated with Iclusig developed serious tumor lysis syndrome. Hyperuricemia occurred in 7% (30/449) of patients overall; the majority had CP-CML (19 patients). Due to the potential for tumor lysis syndrome in patients with advanced disease, ensure adequate hydration and treat high uric acid levels prior to initiating therapy with Iclusig.

Compromised Wound Healing and Gastrointestinal Perforation: Since Iclusig may compromise wound healing, interrupt Iclusig for at least 1 week prior to major surgery. Serious gastrointestinal perforation (fistula) occurred in one patient 38 days post-cholecystectomy.

Embryo-Fetal Toxicity: Iclusig can cause fetal harm. If Iclusig is used during pregnancy, or if the patient becomes pregnant while taking Iclusig, the patient should be apprised of the potential hazard to the fetus. Advise women to avoid pregnancy while taking Iclusig.

Most common non-hematologic adverse reactions: (≥20%) were hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia. Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.

Please see the full U.S. Prescribing Information for Iclusig, including the Boxed Warning, for additional important safety information.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

This press release contains ?forward-looking statements? which are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the Company?s ability to supply Biologics, Inc. with Iclusig; the ability of Biologics, Inc., to deliver contracted-for services, such as specialty pharmacy, distribution, and patient support services, including the management of the Company?s ARIAD PASS program; the timing and success of renewed marketing and sales of Iclusig, including the transition of patients from single-patient IND to commercial or patient assistance product offerings; third-party reimbursement; the FDA?s continued approval of marketing and distribution for Iclusig, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.

Source: ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com  

1529 Postings, 3946 Tage deAlexIch hoffe

 
  
    
17.01.14 13:56
es gibt einen richtigen Schub, die Shorties fangen an zu kokeln und zack stehen wir bei 8,xx USD  

592 Postings, 2173 Tage CapretAnstieg über 7$

 
  
    
2
17.01.14 14:01
müsste doch ne Menge short SL losgetreten haben, werden die auch im Premarkt durchgeführt oder geht die Post dann um 15:30 uhr erst so richtig ab?  

1265 Postings, 2603 Tage sunnyblumMaster neuer thread

 
  
    
17.01.14 14:02
und schon geht es up. :-)  

1529 Postings, 3946 Tage deAlex@Carpet

 
  
    
17.01.14 14:03
die großen kommen in der Regel um 15:30.
Also tippe ich auf 15.30  

Seite: Zurück 1 |
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | 373  Weiter  
   Antwort einfügen - nach oben